Kinrix™: A new combination DTaP-IPV vaccine for children aged 4-6 years

Expert Review of Vaccines

Volumn 7, Issue 9, 2008, Pages 1309-1320

  Weston, Wayde M ^a   Klein, Nicola P ^b  

^a GLAXOSMITHKLINE   (United States)

^b KAISER PERMANENTE   (United States)

Author keywords

Booster; DTaP IPV; Kinrix ; Pertussis; Poliomyelitis; Preschool child

Indexed keywords

DE TE KI POL; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TETANUS ACELLULAR PERTUSSIS INACTIVATED POLIOMYELITIS VACCINE; IPOL; KINRIX; MEASLES MUMPS RUBELLA VACCINE; MMRII; POLIOMYELITIS VACCINE; QUADRACEL; TETRAVAC; UNCLASSIFIED DRUG; VACCINE;

ANOREXIA; ANTIBODY RESPONSE; BOOSTER VACCINATION; DIPHTHERIA; DROWSINESS; DRUG EFFICACY; DRUG MARKETING; DRUG MIXTURE; DRUG SAFETY; FEVER; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; IRRITABILITY; MEASLES; MUMPS; PERTUSSIS; POLIOMYELITIS; PRESCHOOL CHILD; PRIORITY JOURNAL; REVACCINATION; REVIEW; RUBELLA; SIDE EFFECT; SINGLE DRUG DOSE; SWELLING; TETANUS; VACCINATION; CHILD; IMMUNIZATION; IMMUNOLOGY; UNITED STATES;

CHILD; CHILD, PRESCHOOL; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; HUMANS; IMMUNIZATION, SECONDARY; POLIOVIRUS VACCINE, INACTIVATED; UNITED STATES; VACCINES, COMBINED;

EID: 56049095021     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.7.9.1309     Document Type: Review

References (55)

1. Edwards KM, Decker MD. Pertussis vaccine. In: Vaccines (5th Edition). Plotkin SA, Orenstein WA, Offitt P (Eds). Saunders, PA, USA 471-528 (2008).
2. Centers for Disease Control and Prevention. Pertussis vaccination: acellular pertussis vaccine for reinforcing and booster use - supplementary ACIP statement. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm. Rep. 41(RR-1), 1-10 (1992).
3. Plotkin SA, Vidor E. Poliovirus vaccine-inactivated. In: Vaccines (5th Edition). Plotkin SA, Orenstein WA, Offitt P (Eds). Saunders, PA, USA 605-630 (2008).
4. Sutter RW, Kew OM, Cochi SL. Poliovirus vaccine-live. In: Vaccines (5th Edition). Plotkin SA, Orenstein WA, Offitt P (Eds). Saunders, PA, USA 631-686 (2008).
5. Centers for Disease Control and Prevention. Certification of poliomyelitis eradication - the Americas, 1994. MMWR 43(39), 720-722 (1994).
6. Centers for Disease Control and Prevention. Recommended childhood immunization schedule - United States, 1997. MMWR 46(2), 35-40 (1997).
7. Prevots DR, Burr RK, Sutter RW et al. Advisory Committee on Immunization Practices. Poliomyelitis prevention in the United States. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recom. Rep. 49(RR-5), 1-22 (2000).
8. Centers for Disease Control and Prevention. Recommended immunization schedules for persons aged 0-18 years - United States, 2007. MMWR 55(51-52), Q1-Q4 (2006).
9. Meyerhoff AS, Jacobs RJ. Do too many shots due lead to missed vaccination opportunities? Does it matter? Prev. Med. 41(2), 540-544 (2005).
10. Centers for Disease Control and Prevention. Notice to readers: food and drug administration approval of a fifth acellular pertussis vaccine for use among infants and young children - United States, 2002. MMWR 51(26), 574 (2002).
11. Nilsson L, Faldella G, Jacquet JM et al. A fourth dose of DTPa-IPV vaccine given to 4-6 year old children in Italy and Sweden following primary vaccination at 3, 5 and 11-12 months of age. Scand. J. Infect. Dis. 37(3), 221-229 (2005).
12. Jacquet JM, Bégué P, Grimprel E et al. Safety and immunogenicity of a combined DTPa-IPV vaccine administered as a booster from 4 years of age: a review. Vaccine 24(13), 2440-2448 (2006). •• Review of diphtheria toxoid, tetanus toxoid, acellular pertussis and inactivated poliomyelitis vaccine (DTaP-IPV) in 4-7-year-old children. Studies conducted in Europe and Australia.
13. Black S, Friedland LR, Schuind A et al. Immunogenicity and safety of a combined DTaP-IPV vaccine compared with separate DTaP and IPV vaccines when administered as pre-school booster doses with a second dose of MMR vaccine to healthy children aged 4-6 years. Vaccine 24(35-36), 6163-6171 (2006). • Randomized, controlled trial of DTaP-IPV conducted in the USA.
14. Black S, Friedland LR, Ensor K et al. Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4-6 years of age. Pediatr. Infect. Dis. J. 27(4), 341-346 (2008). •• Pivotal, large, randomized, controlled trial of DTaP-IPV conducted in the USA.
15. Marshall H, Nolan T, Roberton D et al. A comparison of booster immunisation with a combination DTPa-IPV vaccine or DTPa plus IPV in separate injections when co-administered with MMR, at age 4-6 years. Vaccine 24(35-36), 6120-6128 (2006). • Randomized, controlled trial of DTaP-IPV conducted in Australia.
16. Centers for Disease Control and Prevention. General recommendations on immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP), US; 2006. MMWR Recomm. Rep. 55(RR-15), 574 (2006).
17. Schmitt HJ, von König CH, Neiss A et al. Efficacy of acellular pertussis vaccine in early childhood after household exposure. JAMA 275(1), 37-41 (1996). • Pivotal study demonstrating efficacy of DTaP (Infanrix™) against pertussis disease.
18. Schmitt HJ, Schuind A, Knuf M et al. Clinical experience of a tricomponent acellular pertussis vaccine combined with diphtheria and tetanus toxoids for primary vaccination in 22,505 infants. J. Pediatr. 129(5), 695-701 (1996)
19. Melville-Smith M, Balfour A. Estimation of Corynebacterium diphtheriae antitoxin in human sera: a comparison of an enzyme-linked immunosorbent assay with the toxin neutralisation test. J. Med. Microbiol. 25(4), 279-283 (1988).
20. Melville-Smith ME, Seagroatt VA, Watkins JT. A comparison of enzyme-linked immunosorbent assay (ELISA) with the toxin neutralization test in mice as a method for the estimation of tetanus antitoxin in human sera. J. Biol. Stand. 11(2), 137-144 (1983).
21. Camargo ME, Silveira L, Furuta JA et al. Immunoenzymatic assay of anti-diphtheric toxin antibodies in human serum. J. Clin. Microbiol. 20(4), 772-774 (1984).
22. Wharton M, Vitek CR. Diphtheria toxoid. In: Vaccines (5th Edition). Plotkin SA, Orenstein WA, Offitt P (Eds). Saunders, PA, USA 211-228 (2008).
23. World Health Organization. Standard procedure for determining immunity to poliovirus using the microneutralization test. WHO/EPI/Gen93.9. Geneva, Switzerland (1993).
24. Granström M, Thorén M, Blennow M et al. Acellular pertussis vaccine in adults: adverse reactions and immune response. Eur. J. Clin. Microbiol. 6(1), 18-21 (1987).
25. Food and Drug Administration Center for Biologics Evaluation and Research. Open session on adult pertussis. Presented at: Proceedings of a Vaccines and Related Products Advisory Committee. Bethesda, MD, USA, 5 June 1997.
26. Greco D, Salmaso S, Mastrantonio P et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group. N. Engl. J. Med. 334(6), 341-348 (1996).
27. Braun MM, Mootrey GT, Salvie ME et al. Infant immunization with acellular pertussis vaccines in the United States: assessment of the first two years' data from the Vaccine Adverse Event Reporting System (VAERS). Pediatrics 106(4), 1-7 (2000).
28. Deloria M, Blackwelder W, Decker M et al. Association of reactions after consecutive acellular or whole-cell pertussis vaccine immunizations. Pediatrics 96, 592-594 (1995).
29. Jackson LA, Dunstan M, Starkovich P et al. Prophylaxis with acetaminophen or ibuprofen for prevention of local reactions to the fifth diphtheria-tetanus toxoids-acellular pertussis vaccination: a randomized, controlled trial. Pediatrics 117(3), 620-625 (2006).
30. Centers for Disease Control and Prevention. Use of diphtheria toxoid-tetanus toxoid-acellular pertussis vaccine as a five-dose series. Supplemental recommendations if the Advisory Committee on Immunization Practices (ACIP). MMWR 49(RR-13), 1-8 (2000).
31. Rennels M, Deloria M, Pichichero M et al. Extensive swelling after booster doses of acellular pertussis-tetanus-diphtheria vaccines. Pediatrics 105, e12 (2000).
32. Scheifle DW, Halperin SA, Ferguson AC. Assessment of injection site reactions to an acellular pertussis-based combination vaccine, including novel use of skin test with vaccine antigens. Vaccine 19, 4720-4726 (2001).
33. Kohl KS, Walop W, Gidudu J et al. Swelling at or near injection site: case definition and guidelines for collection, analysis and presentation of immunization safety data. Vaccine 25(31), 5858-5874 (2007).
34. Schmitt HJ, Beutel K, Schuind A et al. Reactogenicity and immunogenicity of a booster dose of a combined diphtheria, tetanus, and tricomponent acellular pertussis vaccine at fourteen to twenty-eight months of age. J. Pediatr. 130(4), 616-623 (1997).
35. Rennels MB. Extensive swelling reactions occurring after booster doses of diphtheria-tetanus-acellular pertussis vaccines. Semin. Pediatr. Infect. Dis. 14(3), 196-198 (2003). • Review of swelling reactions after booster vaccination.
36. Rowe J, Yerkovich ST, Richmond P et al. Th2-associated local reactions to the acellular diphtheria-tetanus-pertussis vaccine in 4- to 6-year-old children. Infect. Immun, 73(12), 8130-8135 (2005).
37. Southern J, Andrews N, Burrage M et al. Immunogenicity and reactogenicity of combined acellular pertussis/tetanus/low dose diphtheria vaccines given as a booster to UK teenagers. Vaccine 23(29), 3829-3835 (2005).
38. Skowronski DM, Remple VP, Macnabb J et al. Injection-site reactions to booster doses of acellular pertussis vaccine: rate, severity, and anticipated impact. Pediatrics 112(6 Pt 1), e453 (2003).
39. Rennels M, Black S, Woo E et al. Safety of a fifth dose of diphtheria and tetanus toxoid and acellular pertussis vaccine in children experiencing extensive, local reactions to the fourth dose. Pediatr. Infect. Dis. J. 25(5), 1-2 (2008).
40. Langley JM, Predy G, Guasparini R et al. An adolescent-adult formulation tetanus and diphtheria toxoids adsorbed combined with acellular pertussis vaccine has comparable immunogenicity but less reactogenicity in children 4-6 years of age than a pediatric formulation acellular pertussis vaccine and diphtheria and tetanus toxoids adsorbed combined with inactivated poliomyelitis vaccine. Vaccine 25(6), 1121-1125 (2007).
41. Scheifele DW, Halperin SA, Ochnio JJ et al. A modified vaccine reduces the rate of large injection site reactions to the preschool booster dose of diphtheria-tetanus-acellular pertussis vaccine: results of a randomized, controlled trial. Pediatr. Infect. Dis. J. 24(12), 1059-1066 (2005).
42. Centers for Disease Control. Pertussis vaccination: use of acellular pertussis vaccines among infants and young children recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm. Rep. 46(RR-7), 1-25 (1997).
43. Freed GL, Cowan AE, Clark SJ et al. Use of a new combined vaccine in pediatric practices. Pediatrics 118, e251-e257 (2006). • Study in the USA of factors influencing physicians' use of combined vaccines.
44. Happe LE, Lunacsek OE, Marshall GS et al. Combination vaccine use and vaccination quality in a managed care population. Am. J. Manag. Care 13(9), 506-512 (2007). • Study in the USA assessing the impact of a combination vaccine on coverage rates and timeliness.
45. Marshall GS, Happe LE, Lunacsek OE et al. Use of combination vaccines is associated with improved coverage rates. Pediatr. Infect. Dis. J. 26, 496-500 (2007).
46. Kalies H, Grote V, Verstraeten T et al. The use of combination vaccines has improved timeliness of vaccination in children. Pediatr. Infect. Dis. J. 25(6), 507-512 (2006).
47. World Health Organization. Inactivated poliovirus vaccine following oral poliovirus vaccine cessation. Supplement to the WHO position paper. Wkly Epidemiol. Rec. 81, 137-144 (2006).
48. Broder KR, Cortese MM, Iskander JK et al. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 55(RR-3), 1-34 (2004).
49. Kretsinger K, Broder KR, Cortese MM et al. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel. MMWR Recomm. Rep. 55(RR-17), 1-37 (2006).
50. Huang LM, Chang LY, Tang H et al. Immunogenicity and reactogenicity of a reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine in healthy Taiwanese children and adolescents. J. Adolesc. Health 37(6), 517 (2005).
51. Kosuwon P, Warachit B, Hutagalung Y et al. Reactogenicity and immunogenicity of reduced antigen content diphtheria-tetanus-acellular pertussis vaccine (dTpa) administered as a booster to 4-6 year-old children primed with four doses of whole-cell pertussis vaccine. Vaccine 21(27-30), 4194-4200 (2003).
52. Sänger R, Behre U, Krause KH et al. Booster vaccination and 1-year follow-up of 4-8-year-old children with a reduced-antigen-content dTpa-IPV vaccine. Eur. J. Pediatr. 166(12), 1229-1236 (2007).
53. Robert Koch-Institut: Empfehlung der Ständigen Impfkommission (STIKO) am Robert Koch-Institut zur Pertussis-Schutzimpfung. Epidemiologisches Bulletin 3, 21-23 (2006).
54. Zepp F, Habermehl P, Knuf M et al. Immunogenicity of reduced antigen content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine. Vaccine 25(29), 5248-5252 (2007).
55. NHS Routine childhood immunization programme. January 2008 www.immunisation.nhs.uk/immunisation_schedule